Delivery of chemotherapeutic drugs in tumour cell-derived microparticles

Ke Tang, Yi Zhang, Huafeng Zhang, Pingwei Xu, Jing Liu, Jingwei Ma, Meng Lv, Dapeng Li, Foad Katirai, Guan-Xin Shen, Guimei Zhang, Zuo-Hua Feng, Duyun Ye, Bo Huang, Ke Tang, Yi Zhang, Huafeng Zhang, Pingwei Xu, Jing Liu, Jingwei Ma, Meng Lv, Dapeng Li, Foad Katirai, Guan-Xin Shen, Guimei Zhang, Zuo-Hua Feng, Duyun Ye, Bo Huang

Abstract

Cellular microparticles are vesicular plasma membrane fragments with a diameter of 100-1,000 nanometres that are shed by cells in response to various physiological and artificial stimuli. Here we demonstrate that tumour cell-derived microparticles can be used as vectors to deliver chemotherapeutic drugs. We show that tumour cells incubated with chemotherapeutic drugs package these drugs into microparticles, which can be collected and used to effectively kill tumour cells in murine tumour models without typical side effects. We describe several mechanisms involved in this process, including uptake of drug-containing microparticles by tumour cells, synthesis of additional drug-packaging microparticles by these cells that contribute to the cytotoxic effect and the inhibition of drug efflux from tumour cells. This study highlights a novel drug delivery strategy with potential clinical application.

References

    1. Science. 2010 Jan 29;327(5965):580-3
    1. Cell. 2007 Nov 30;131(5):840-2
    1. Cancer Res. 2011 Feb 15;71(4):1442-53
    1. Nat Rev Immunol. 2009 Aug;9(8):581-93
    1. Semin Thromb Hemost. 2010 Nov;36(8):857-64
    1. Cancer Res. 1997 Feb 15;57(4):765-72
    1. Cancer Res. 1999 Aug 15;59(16):4129-35
    1. J Cell Biol. 2011 Aug 22;194(4):613-29
    1. ACS Nano. 2010 Sep 28;4(9):4967-70
    1. Nat Rev Mol Cell Biol. 2010 Oct;11(10):688-99
    1. Blood. 2011 Jun 16;117(24):6612-6
    1. Proc Natl Acad Sci U S A. 2011 Aug 16;108(33):13552-7
    1. Lancet Oncol. 2006 Nov;7(11):925-34
    1. J Clin Invest. 1997 May 1;99(9):2118-27
    1. Int J Pharm. 2010 Jul 15;394(1-2):115-21
    1. Physiology (Bethesda). 2005 Feb;20:22-7
    1. Int J Cancer. 2011 Jul 1;129(1):233-44
    1. Clin Cancer Res. 2008 Jul 1;14(13):4134-40
    1. J Autoimmun. 2011 May;36(3-4):173-80
    1. Biochem Biophys Res Commun. 2010 Sep 24;400(3):432-6
    1. J Clin Invest. 1999 Jul;104(1):93-102
    1. Br J Haematol. 1967 May;13(3):269-88
    1. Nat Rev Mol Cell Biol. 2006 Dec;7(12):897-908
    1. Small. 2008 Jan;4(1):26-49
    1. Cancer Res. 2010 Jul 15;70(14):5728-39
    1. Blood. 2005 Sep 1;106(5):1604-11
    1. Blood. 2007 Nov 15;110(10):3547-51
    1. Mol Cancer Ther. 2008 Apr;7(4):788-99
    1. J Urol. 2007 Apr;177(4):1335-8
    1. Proc Natl Acad Sci U S A. 2004 Jun 22;101(25):9263-5
    1. Nat Mater. 2006 Apr;5(4):245-8
    1. Mol Pharm. 2011 Jun 6;8(3):683-700
    1. Nat Rev Immunol. 2009 Apr;9(4):259-70
    1. Nature. 2007 Apr 12;446(7137):749-57
    1. Annu Rev Pharmacol Toxicol. 2010;50:63-88
    1. Circ Res. 2010 Oct 29;107(9):1047-57
    1. J Pharm Pharmacol. 2009 Feb;61(2):131-42
    1. PLoS One. 2011 Mar 23;6(3):e17223
    1. Curr Opin Immunol. 2002 Feb;14(1):136-45
    1. Cancer Res. 2006 Apr 1;66(7):3629-38
    1. J Biol Chem. 1999 Nov 19;274(47):33398-402
    1. Cancer Res. 2003 Aug 1;63(15):4331-7
    1. Nat Rev Clin Oncol. 2010 Nov;7(11):653-64
    1. Blood. 2011 Jan 27;117(4):e39-48
    1. Biomaterials. 2007 Jul;28(19):3026-33
    1. Am J Pathol. 2010 Sep;177(3):1053-64
    1. Science. 2011 Mar 25;331(6024):1559-64
    1. Proc Natl Acad Sci U S A. 2008 Jul 8;105(27):9343-8
    1. Curr Cancer Drug Targets. 2011 Feb;11(2):135-46
    1. Curr Biol. 2011 Jul 26;21(14):1167-75
    1. J Leukoc Biol. 1996 Jan;59(1):100-15
    1. Nat Rev Drug Discov. 2010 Jan;9(1):29-42
    1. Nat Rev Cancer. 2010 Feb;10(2):147-56
    1. Apoptosis. 2005 Aug;10(4):731-41
    1. Br J Cancer. 2008 Aug 5;99(3):392-7
    1. Leukemia. 2006 Sep;20(9):1487-95
    1. J Exp Med. 2008 Jun 9;205(6):1261-8

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi